Latest News
Integra Therapeutics, a biotechnology company that creates next- generation gene writing tools, has closed an additional EUR1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the EUR4.5 million Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures and completes its seed round in line with the company’s set goals.
The new funds will go to support development of the FiCAT platform prototype and preclinical validation with in vivo and ex vivo models.
Charme Capital Partners (Charme), a pan-European mid-market private equity firm, and Amadeus Capital Partners (Amadeus), are to sell 100 per cent of Veritas Intercontinental to LetsGetChecked, a global healthcare solutions company.
LetsGetChecked, which is based in Dublin and New-York, the tools to manage health from home through direct access to diagnostic testing, virtual care, and medication delivery for a wide range of health and wellness conditions.
Veritas Intercontinental was founded in 2018 as a spin-off from Veritas Genetics and has led the activity and development of the Veritas brand outside of the United States, offering a wide range of genomic
Arowana Impact Capital (AIC), the impact investing arm of global B Corp investment group, Arowana, has completed a cornerstone investment in Green Antz, producer of eco-friendly construction materials operating in Southeast Asia.
Green Antz converts plastic waste from commercial establishments and communities into value-added construction materials, such as bricks and pavers. Green Antz does this through its network of EcoHubs across the Philippines, which serve as collection sites, production facilities, and recycling education centres.
This strategy enables Green Antz to tackle Asia’s burgeoning plastic waste problem, whilst offering cost-effective and environmentally responsible alternatives to traditional building materials.
Stanley Capital (SCP), a mid-market private equity firm focused on growing sustainable businesses in the Healthcare, Technology and Resource Efficiency sectors, and Applied Artificial Intelligence Corporation (AAICO), a artificial intelligence (AI) technology company headquartered in the UAE, are partnering to bring artificial intelligence to private equity investing.
The partnership will entail using AAICO’s proprietary AI technologies within Stanley Labs (‘S-Labs’), Stanley Capital’s technology arm, which focuses on developing and using AI and automation products to identify, evaluate and create value within SCP, its Healthcare Services and Software Special Purpose Acquisition Vehicle (‘SPAC’), and its portfolio companies.
AAICO and Stanley Capital
2022 will be the year the level of in-person and online meetings rebalance to create a new fundraising ‘normal’ for years to come…
The private market fundraising process underwent a historic transformation through the various stages of Covid-19, but many of the adjustments made during 2020 and 2021 are now being reviewed by GPs and LPs as travel restrictions and lockdowns ease in the UK, Europe and the US.
In 2020 fund managers relied mainly on existing relationships to raise and close funds virtually. Last year saw a shift back to engaging with new clients.
“In 2021, the situation largely
By Colin Leopold – Large institutional investors in Japan and South Korea are increasing their overseas private equity exposure but the process has been slow. A booming private wealth market could be quicker…
By Colin Leopold – Rising public market valuations and tech-based disruption has pushed investors towards sector specialist managers. Demand is now building for more general macro strategies too…
IntelleWings Private Limited, an AI-powered and SaaS enabled AML/CFT (Combating the Financing of Terrorism) Compliance company, has raised USD650 thousand in pre-Series A round from Dallas Venture Capital (DVC), a cross-border venture capital firm focused on early and growth stage companies in cloud infrastructure, B2B SaaS, AI/ML, mobile, XR and other emerging technologies.
The round saw existing investors including SucSEED Indovation Fund, Padup Ventures and Vinners, reinforce their support with additional capital along with the participation of new investors Lead Angels and Nextgen Technology Fund I (a fund created by STPI and managed by Pontaq).
Crestbridge, a global provider of independent private equity and real estate administration solutions, has appointed Luke Hamill as Director, Corporate and Capital Markets.
Following the appointment at the beginning of the year of Martin Lambert as Group Head, Corporate and Capital Markets, Hamill who will be based in London, joins the Corporate Services team, and will focus his experience on further developing the Crestbridge capital markets proposition.
With more than two decades of experience in the international real estate industry, Hamill has spent the last six years based in Abu Dhabi working for the Abu Dhabi Investment Authority (ADIA) where
Blue Horizon, a pure play impact investor in the future of food, has made a seed investment in Core Biogenesis which uses plants as biofactories to scale the production of high-value bioproducts like growth factors.
Blue Horizon invested in Core Biogenesis, a French startup focusing on the production of growth factors for applications in both cell therapy and cultivated meat. Core Biogenesis’ plant-based production platform has delivered several functional growth factors to date and provides unique cost-efficiency at large scale.
The current funding round will enable Core Biogenesis to expand the team that scales up production in a new facility
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
